Primary Hyperparathyroidism

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 767-777

  Silverberg, Shonni J ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751237164     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50047-9     Document Type: Chapter

References (104)

1. Albright H., Reifenstein E.C. The Parathyroid Glands and Metabolic Bone Disease 1948, Williams & Wilkins, Baltimore, MD.
2. Cope O. The story of hyperparathyroidism at the Massachusetts General Hospital. N. Engl. J. Med. 1966, 21:1174-1182.
3. Bauer W. Hyperparathyroidism: Distinct disease entity. J. Bone J. Surg. 1933, 15:135-141.
4. Bauer W., Federman D.D. Hyperparathyroidism epitomized: Case of Captain Charles E. Martell. Metab. Clin. Exp. 1962, 11:21-22.
5. Mandl F. Therapeutischer Versuch bei Ostitis fibrosa generalisata mittels Extirpation eines Epithelkoerperchentumors. Wien. Klin. Wochenschr. 1925, 50:1343-1344.
6. Albright P., Aub J.C., Bauer W. Hyperparathyroidism common and polymorphic condition as illustrated by seventeen proved cases from one clinic. JAMA 1934, 102:1276-1287.
7. Silverberg S.J., Bilezikian J.P. Primary hyperparathyroidism. Principles and Practice of Endocrinology and Metabolism 2001, 564-573. Lippincott-Williams & Wilkins, New York. K.L. Becker (Ed.).
8. Heath H., Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism: Incidence, morbidity, and economic impact in a community. N. Engl. J. Med. 1980, 302:189-193.
9. Mundy G.R., Cove D.H., Friskin R. Primary hyperparathyroidism: Changes in the pattern of clinical presentation. Lancet 1980, 1:1317-1320.
10. Schulz D.A., Pummel D.C. Asymptomatic primary hyperparathyroidism. Mayo Clin. Proc. 1981, 56:473-478.
11. Silverberg S.J., Bilezikian J.P. Clinical presentation of primary hyperparthyroidism in the United States. The Parathyroids 2001, 349-360. Academic Press, New York. 2nd edn. J.P. Bilezikian, R. Marcus, M.A. Levine (Eds.).
12. Rio S.D., Frame B., Miller M.-J., Kleerekoper M., Block M.A., Parfitt A.M. Hyperparathyroidism following head and neck irradiation. Arch. Intern. Med. 1980, 140:205-207.
13. Seely E.W., Moore T.J., LeBoff M.S., Brown E.M. A single dose of lithium carbonate acutely elevates intact parathyroid hormone levels in humans. Acta Endocrinol. 1989, 121:174-176.
14. Nordenstrom J., Strigard K., Perbeck L., Willems J., Bagedahl-Strindlund M., Under J. Hyperparathyroidism associated with treatment of manic-depressive disorders by lithium. Ear. J. Surg. 1992, 158:207-211.
15. McHenry C.R., Rosen I.B., Rotstein L.E., Forbath N., Walfish P.G. Lithiumogenic disorders of the thyroid and parathyroid glands as surgical disease. Surgery 1989, 108:1001-1005.
16. Krivitzky A., Bentata-Pessayre M., Sarfati E., Gardin J.P., Callard P., Delzant G. Multiple hypersecreting lesions of the parathyroid glands during treatment with lithium. Ann. Med. Intern. 1986, 137:118-122.
17. Arnold A., Staunton C.E., Kirn H.G., Gaz R.D., Kronenberg H.M. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N. Engl. J. Med. 1988, 318:658-662.
18. Arnold A., Kirn H.G. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J. Clin. Invest. 1989, 83:2034-2040.
19. Friedman E., Bale A.E., Marx S.J., et al. Genetic abnormalities in sporadic parathyroid adenoma. J. Clin. Endocrinol. Metab. 1990, 71:293-297.
20. Arnold A., Kim H.G. Clonal loss of one chromosome 11 in a parathyroid adenoma. Clin. Endocrinol. Metab. 1989, 69:496-499.
21. Cryns V.L., Yi S.M., Tahara H., Gaz R.D., Arnold A. Frequent loss of chromosome arm I p in parathyroid adenomas. Genes Chromosomes Cancer 1995, 13:9-17.
22. Tahara H., Smith A.P., Gaz R.D., Cryns V.L., Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 1996, 56:599-605.
23. Carling T., Correa P., Hessman O., Hedberg J., Skogseid B., Lindberg D., Rastad J., Westin G., Akerstrom G. Parathyroid MENI gene mutations in relation to clinical characteristics of non-familial primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1999, 83:2960-2963.
24. Brown E.M., Gardner D.G., Brennan M.F., et al. Calcium-regulated parathyroid hormone release in primary hyperparathyroidism. Studies in vitro with dispersed parathyroid cells. Am. J. Med. 1979, 66:923-931.
25. Lloyd H.M., Parfitt A.M., Jacobi J.M., et al. The parathyroid glands in chronic renal failure: A study of their growth and other properties made on the basis of findings in patients with hypercalcemia. Lab. Clin. Med. 1989, 114:358-367.
26. Ringe J.D. Reversible hypertension in primary hyperparathyroidism: Pre- and postoperative blood pressure in 75 cases. Klin. Wochenschr. 1984, 62:465-469.
27. Broulik P.D., Horky K., Pacovsky V. Blood pressure in patients with primary hyperparathyroidism before and after parathyroidectomy. Exp. Clin. Endocrinol. 1985, 86:346-352.
28. Rapado A. Arterial hypertension and primary hyperparathyroidism. Am. J. Nephrol. 1986, 6(Suppl. 1):46-50.
29. Bilezikian J.P., Aurbach G.D., Connor T.B., et al. Pseudogout following parathyroidectomy. Lancet 1973, 1:445-447.
30. Geelhoed G.W., Kelly T.R. Pseudogout as a clue and complication in primary hyperparathyroidism. Surgery 1989, 106:1036-1041.
31. Joborn C., Hetta J., Johansson H., et al. Psychiatric morbidity in primary hyperparathyroidism. World J. Surg. 1988, 12:476-481.
32. Brown G.G., Preisman R.C., Kleerekoper M.D. Neurobehavioral symptoms in mild primary hyperparathyroidism: Related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Med. 1987, 7:211-215.
33. Roam D.S., Phillips E.R., Divine G.W., Talpos G.B. Randomized controlled clinical trail of surgery vs no surgery in patients with mild asymptomatic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2004, 89:5414-5422.
34. Silverberg S.J. Non-classical target organs in primary hyperparathyroidism. J. Bone Min. Res. 2002, 17(suppl 2):N117-N125.
35. Silverberg S.J., Brown I., LoGerfo P., Gao P., Cantor T., Bilezikian J.P. Clinicalutility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2003, 88:4725-4730.
36. Vieth R., Bayley T.A., Walfish P.G., Rosen I.B., Pollard A. Relevance of vitamin D metabolite concentrations in supporting the diagnosis of primary hyperparathyroidism. Surgery 1991, 110:1043-1046.
37. Silverberg S.J., Shane E., Dempster D.W., Bilezikian J.P. Vitamin D deficiency in primary hyperparathyroidism. Am. J. Med. 1999, 107:561-567.
38. Mithal A., Bandeira F., Meng X., Silverberg S.J., Shi Y., Mishra S.K., Griz L., Macedo G., Celdas G., Bandeira C., Bilezikian J.P., Rao S.D. Clinical presentation of primary hyperparthyroidism: India, Brazil and China. The Parathyroids 2001, 375-386. Academic Press, New York. 2nd edition. J.P. Bilezikian, R. Marcus, M.A. Levine (Eds.).
39. Klugman V.A., Favus M., Pak C.Y.C. Nephrolithiasis in primary hyperparathyroidism. The Parathyroids: Basic and Clinical Concepts 1994, 505-518. Raven Press, New York. J.P. Bilezikian (Ed.).
40. Silverberg S.J., Shane E., Jacobs T.P., et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am. J. Med. 1990, 89:327-334.
41. Patten B.M., Bilezikian J.P., Mallette L.E., Prince A., Engel W.K., Aurbach G.D. The neuromuscular disease of hyperparathyroidism. Ann. Intern. Med. 1989, 80:182-194.
42. Turken S.A., Cafferty M., Silverberg S.J., et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am. J. Med. 1989, 87:553-557.
43. Silverberg S.J., Shane E., De La Cruz L., et al. Skeletal disease in primary hyperparathyroidism. J. Bone Miner. Rex. 1989, 4:283-291.
44. Bilezikian J.P., Potts J.T., El-Hajj Fuleihan G., Kleerekoper M., Neer R., Peacock M., Rastad J., Silverberg S.J., Udelsman R., Wells S.A. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21 st century. J. Clin. Endocrinol. Metab. 2002, 87:5353-5361.
45. National Institutes of Health Consensus development conference statement on primary hyperparathyroidism. J. Bone Miner. Res. 1991, 6:s9-s93.
46. Silverberg S.J., Locker F.G., Bilezikian J.P. Vertebral osteopenia: A new indication for surgery in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1996, 81:4007-4012.
47. Parisien M., Silverberg S.J., Shane E., et al. The histormorphometry of bone in primary hyperparathyroidism: Preservation of cancellous bone structure. Clin. Endocrinol. Metab. 1990, 70:930-938.
48. Parfitt A.M. Surface specific bone remodeling in health and disease. Clinical Disorders of Bone and Mineral Metabolism 1989, 7-14. Mary Ann Liebert, New York. M. Kleerekoper (Ed.).
49. Dempster D.W., Parisien M., Silverberg S.J., et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1999, 84:1562-1566.
50. Parisien M., Cosman F., Mellish R.W.E., et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J. Bone Miner. Res. 1995, 10:1393-1399.
51. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., Shane E., Plavetic K., Muller R., Bilezikian J., Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Min. Res. 2001, 16:1846-1853.
52. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsma A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitalk B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344:1434-1441.
53. Khosla S., Melton L.J., Wermers R.A., et al. Primary hyperparathyroidism and the risk of fracture: A population-based study. J. Bone Miner. Res. 1999, 14:1700-1707.
54. Kochesberger G., Buckley N.J., Leight G.S., et al. What is the clinical significance of bone loss in primary hyperparathyroidism. Arch. Intern. Med. 1987, 147:1951-1953.
55. Wilson R.J., Rao S., Ellis B., et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann. Intern. Med. 1988, 109:959-962.
56. Larsson K., Ljunghall S., Krusemo U.B., et al. The risk of hip fractures in patients with primary hyperparathyroidism: A population-based cohort study with a follow-up of 19 years. J. Intern. Med. 1993, 234:585-593.
57. Kenny A.M., MacGillivray D.C., Pilbeam C.C., et al. Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 1995, 118:109-114.
58. Dauphine R.T., Riggs B.L., Scholz D.A. Back pain and vertebral crush fractures: An unemphasized mode of presentation for primary hyperparathyroidism. Ann. Intern. Med. 1975, 83:365-367.
59. Deftos L.J. Markers of bone turnover in primary hyperparathyroidism. The Parathyroids: Basic and Clinical Concepts 1994, 485-492. Raven Press, New York. J.-P. Bilezikian (Ed.).
60. Moss D.W. Perspectives in alkaline phosphatase research. Clin. Chem. 1992, 38:2486-2492.
61. Silverberg S.J., Deftos L.J., Kim T., Hill C.S. Bone alkaline phosphatase in primary hyperparathyroidism. J. Bone Miner. Res. 1991, 6:A624.
62. Duda R.J., O'Brien J.K., Katzman J.A., Paterson J.M., Mann K.G., Riggs B.L. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: Effects of sex, age, and metabolic bone disease. J. Clin. Endocrinol. Metab. 1988, 5:1-7.
63. Price P.A., Parthemore J.G., Deftos L.J. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone Gla-protein in the plasma of normal subjects and patients with bone disease. J. Clin. Invest. 1980, 66:878-883.
64. Deftos L.J., Parthemore J.G., Price P.A. Changes in plasma bone Gla-protein during treatment of bone disease. Calcif. Tissue Int. 1982, 34:121-124.
65. Eastell R., Delmas P.D., Hodgson S., Eriksen E.E., Mann K.M., Riggs B.L. Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J. Clin. Endocrinol. Metab. 1988, 67:741-748.
66. Ebeling P.R., Peterson J.M., Riggs B.L. Utility of type 1 procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 1992, 7:1243-1250.
67. Minisola S., Romagnoli E., Scarnecchia L., Rosso R., Pacitti M.T.-, Scarda A., Mazzuoli G. Scrum CITP in patients with primary hyperparathyroidism: Studies in basal conditions and after parathyroid surgery. Eur. J. Endocrinol. 1994, 130:587-591.
68. Seibel M.J., Gartenberg F., Silverberg S.J., Ratcliffe A., Robins S.P., Bilezikian J.P. Urinary hydroxypyridinium crosslinks of collagen in primary hyperparathyroidism. Clin. Endocrinol. Metab. 1992, 74:481-486.
69. Charles P., Mosekilde L., Risteli L., Eriksen E.F. Assessment of bone remodeling using biochemical indicators of type 1 collagen synthesis and degredation: Relation to calcium kinetics. Bone Miner. 1994, 24:81-94.
70. Eriksen E.F., Charles P., Melsen K., Mosekilde L., Ristei L., Risteli J. Serum markers of type 1 collagen formation and degredation in metabolic bone diseases: Correlation with bone histomorphometry. J. Bone Miner. Res. 1993, 8:127-132.
71. Kraenzlin M.E., Lau K.H.W., Liang L., et al. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. Clin. Endocrinol. Metab. 1990, 71:442.
72. De La Piedra C., Diaz Martin M.A., Diaz Diego E.M., Lopez Gavilanes E., Gonzalez Parra E., Carmelo C., Rapado A. Serum ICTP, serum tartrate resistant acid phosphatase, and serum levels of intact FIH in parathyroid hyperfunction. Scand. J. Clin. Lab. Invest. 1994, 54:11-15.
73. Seibel M.J., Woigte H.W., Pecherstorfer M., Karmatschek M., Horn E., Ludwig M., Armbruster F.P., Ziegler R. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant diseases. J. Clin. Endocrinol. Metab. 1996, 81:3289-3294.
74. Guo C.Y., Thomas W.E.R., Al-Dehaimi A.W., Assiri A.M.A., Eastell R. Longitudinal changes in bone mineral density and bone turnover in women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1996, 81:3487-3491.
75. Tanaka Y., Funahashi H., Imai T., Tominga Y., Takagi H. Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin. Surg. Oncol. 1997, 13:125-133.
76. Hoshino H., Kushida K., Takahashi M., Denda M., Yamazaki K., Yamanashi A., Inoue T. Short term effect of parathyroidectomy on biochemical markers in primary and secondary hyperparathyroidism. Miner: Electrolyte Metab. 1997, 23:93-99.
77. Grey A., Mitnick M., Shapses S., Gundberg C., Insogna K. Circulating levels of IL-6 and TNF-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption. J. Clin. Endocrinol. Metab. 1996, 81:3450-3454.
78. Roodman G.D. Interleukin-6: An osteotropic factor?. Bone Miner: Res. 1992, 1:475-478.
79. Greenfield E.M., Shaw S.M., Gomik S.A., Banks M.A. Adenyl cyclase and interleukin 6 are down stream effectors of PTH resulting in stimulation of bone resorption. J. Clin. Invest. 1995, 96:1238-1244.
80. Rusinko R., Yin J.J., Yee J., Saad G.R. PTH excess is associated with increased IL-6 and soluble IL-6 receptor production. Bone Miner: Res. 1995, 10(Suppl. 1):T585A.
81. Jones J.L., Clemmons D.R. Insulin-like growth factors and their binding proteins. Endocr. Rev. 1995, 15:3-34.
82. Spencer E.M., Si E.C., Liu C-C., Howard G.A. PTH potentiates the effect of IGF-1 on bone formation. Acta Endocrinol. 1989, 121:435-442.
83. McCarthy T.L., Centrella M.C., Canalis E. PTH enhances the transcript and polypetide levels of IGF-1 in osteoblast enriched cultures from fetal rat bone. J. Clin. Endocrinol. Metab. 1989, 124:1247-1253.
84. Pfeilschifter J., Laukhuf P., Muller-Beckmann B., Blum W.F., Pfister T., Ziegler R. PTH increases the concentration of IGF-1 and TGF-B1 in rat bone. J. Clin. Invest. 1995, 96:767-774.
85. Deaconson T.E., Wilson S.D., Lemann J. The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery 1987, 215:241-251.
86. Silverberg S.J., Shane E., Jacobs T.P., Siris E., Bilezikian J.P. The natural history of treated and untreated asymptomatic primary hyperparathyroidism: a ten-year prospective study. N. Engl. J. Med. 1999, 341:1249-1255.
87. Rao D.S., Wilson R.J., Kleerekoper M., Parfitt A.M. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1988, 67:1294-1298.
88. Silverberg S.J., Brown I., Bilezikian J.P. Youthfulness as a criterion for surgery in primary hyperparathyroidism. Am. J. Med. 2002, 113:681-684.
89. Purnell D.C., Scholz D.A., Smith L.M., et al. Treatment of primary hyperparathyroidism. Am. J. Med. 1984, 56:800-809.
90. Broadus A.E., Magee J.S., Mallette L.E., et al. A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1983, 56:953-961.
91. Kaplan R.A., Geho W.B., Poindexter C., et al. Metabolic effects of diphosphonate in primary hyperparathyroidism. J. Clin. Pharmacol. 1977, 17:410-419.
92. Shane E., Baquiran D.C., Bilezikian J.P. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann. Intern. Med. 1981, 95:23-27.
93. Hassani S., Braunstein G.D., Seibel M.J., Brickman A.S., Geola F.L., Pekary A.E., Hershman J.M. Alendronate therapy of primary hyperparathyroidism. Endocrinologist 2001, 11:459-464.
94. Rossini M., Gatti D., Isaia G., Sartori L., Braga V., Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J. Bone Miner: Res. 2001, 16:113-119.
95. Parker C.R., Blackwell P.J., Fairbaim K.J., Hosking D.J. Hyperparathyroid-Related osteoporosis: A 2-Year Study. J. Clin. Endocrinol. Metab. 2002, 87:4482-4489.
96. Chow C.C., Chan W.B., Li J.K.Y., Chan N.N., Chan M.H.M., Ko G.T.C., Lo K.W., Cockram C.S. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2003, 88:581-587.
97. Kahn A.A., Bilezikiam J.P., Kung A.W.C., Ahmed M.M., Dubois S.J., Ho A.Y.Y., Schussheim D., Rubin M.R., Shaikh A.M., Silverberg S.J., Standish T.I., Syed Z., Syed Z.A. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2004.
98. Gallagher J.C., Nordin B.E.C. Treatment with oestrogens of primary hyperparathyroidism in postmenopausal women. Lancet 1972, 1:503-507.
99. Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J. Bone Min. Res. 2002, 17(Suppl 2):N146-N149.
100. Selby P.L., Peacock M. Ethinyl estradiol and norethinedrone in the treatment of primary hyperparathyroidism in postmenopausal women. N. Engl. J. Med. 1986, 314:1481-1485.
101. Grey A.B., Stapleton J.P., Evans M.C., et al. Effect of hormone replacement therapy on BMD in postmenopausal women with primary hyperparathyroidism. Ann. Intern. Med. 1996, 125:360-368.
102. Rubin M.A., Lee K.H., McMahon D.J., Silverberg S.J. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2003, 88:1174-1178.
103. Silverberg S.J., Mariott T.B., Bone H.G., et al. Short term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism. N. Engl. J. Med. 1997, 307:1506-1510.
104. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., Peacock M. The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2003, 88:5644-5649.